Jellagen® announces new Chairman of the Board, Gregg Sando.18/02/20
Jellagen Ltd, the leading provider of next generation collagen products from marine sources, announces the appointment of Gregg Sando as Chairman of the Board and Non-Executive Director. Gregg replaces Stephane Thiroloix who will remain as a non-executive director at Jellagen.
Gregg founded one of the first cancer immunotherapy biotech companies in 2005 and has pioneered the commercialization of innovative cell therapies for oncology and infectious diseases. Gregg studied biochemistry at Harvard and then received an MBA from the University of Chicago. His business career started on Wall Street where he progressed to manage global advisory groups for two leading investment banks.
Returning to his lifelong passion for science, Gregg left investment banking in 2004 and entered the postgraduate research program at the Imperial College London Medical School where he earned an MSc in Immunology. His research work focused on the therapeutic management of immune stimulation and inhibition pathways which provided the basis for the launch of his cancer immunotherapy company, backed by the Wellcome Trust and venture capital investors.
Gregg is also an investor, adviser and Board Director in several start-up life sciences companies as well as a mentor for young entrepreneurs launching biotech start-ups.
Thomas-Paul Descamps, Chief Executive Officer, commented:
“Having Gregg Sando join the Jellagen team is a great sign for our investors and for the company. We would like to thank Stéphane Thiroloix for his dedication and insight in helping us to build up the company’s sales and marketing infrastructure for its cell culture product line, while also establishing a strong IP portfolio around the application and manufacturing of marine collagen. We are very pleased that he stays at the Board ensuring both a smooth transition and the continuity of our market strategy for research-grade products. Gregg will now help us take Jellagen to the next level through his recent experience in pioneering novel drug development program based on new biotechnologies as well as his deep understanding of corporate finance and governance from his previous investment banking career”.
Gregg Sando, Chairman of the Board, commented:
“Jellagen is a highly innovative biomaterials company manufacturing a differentiated collagen product for a range of applications. There is great potential for marine based collagen to replace mammalian products in the cell culture market and indeed to open the door for new high value medical uses. I look forward to working with the company to achieve the benefits of marine collagen for patients with rare skin diseases or in need of tissue reconstruction as well as more generally to improve cell culture research”.